Reefer Madness : A Case of Cannabis-Induced Psychosis Matthew C. Ballenberger, Robert D. Glatter, Daniel P. Klein, Steven Mandel, Medscape Psychiatry, August 15, 2019 Clinical Presentation A 32-year-old woman with a history of iron-deficiency anemia was brought in by ambulance because of altered mental status. The patient's sister and boyfriend reported that 1 day before presentation, the patient had ingested a marijuana edible and a few hours later developed fatigue and nausea, followed by at least 15 episodes of nonbloody, nonbilious, projectile vomiting throughout the night. In the morning, she became very pale, her lips turned blue, and she became stiff, losing consciousness for [...]
Lire la suiteAcute Effects of Lysergic Acid Diethylamide in Healthy Subjects Yasmin Schmid, Florian Enzler, Peter Gasser, Eric Grouzmann, Katrin H. Preller, Franz X. Vollenweider, Rudolf Brenneisen, Felix Müller, Stefan Borgwardt, and Matthias E. Liechti Biological Psychiatry, 2014, Vol. 78, 8, 544-553 http://dx.doi.org/10.1016/j.biopsych.2014.11.015 ABSTRACT BACKGROUND : After no research in humans for .40 years, there is renewed interest in using lysergic acid diethylamide (LSD) in clinical psychiatric research and practice. There are no modern studies on the subjective and autonomic effects of LSD, and its endocrine effects are unknown. In animals, LSD disrupts prepulse inhibition (PPI) of the acoustic startle response, and patients with schizophrenia exhibit similar [...]
Lire la suiteModel Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction Nicolas A. Bercel, Lee E. Travis, Leonard B. Olinger & E. Dreikurs AMA Archives of Neurology and Psychiatry, 1956, 588-611 republishing :Psychopathology: A Source Book (pp. 605–639). DOI: https://doi.org/10.4159/harvard.9780674367012 Keywords : Cardiovascular Agents, Ergot Alkaloids, adverse effects, Lysergic Acid Diethylamide, Mental Disorders, Oxytocics, Paranoid Disorders, Psychotic Disorders INTRODUCTION Experimental psychosis has a long history. It might have started with the administration of Cannabis indica boiling in wine to the ancient Hun warriors, resulting in mental obfuscation, as they were prepared for surgery because of wounds sustained in battle. [...]
Lire la suiteSub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution M. V. Uthaug, K. van Oorsouw, K. P. C. Kuypers, M. van Boxtel, N. J. Broers, N. L. Mason, S. W. Toennes, J. Riba, J. G. Ramaekers Psychopharmacology, 2018 https://doi.org/10.1007/s00213-018-4988-3 Abstract Rationale : Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on [...]
Lire la suiteHallucinogen persisting perception disorder after psilocybin consumption : a case study Marie-Laure Espiard, Laurent Lecardeur, Pascale Abadie, Isabelle Halbecq, Sonia Dolfuss European Psychiatry, 2005, 20, (5-6), 458-60 DOI: 10.1016/j.eurpsy.2005.04.008 Abstract The recurrence of flashbacks without acute or chronic hallucinogen consumption has been recognized in the DSM IV criteria as the hallucinogen persisting perception disorder (HPPD). Perceptual disturbances may last for 5 years or more and represent a real psychosocial distress. We reported here a case of a 18 year-old young man presenting HPPD after a mixed intoxication with psylocibin and cannabis. This report shows symptomatic recurrences persisting more than 8 months. Various differential diagnoses were [...]
Lire la suiteSurvey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2016, 1 –11 DOI: 10.1177/0269881116662634 Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging [...]
Lire la suiteHarm potential of magic mushroom use : A review Jan van AMSTERDAM, Antoon OPPERTHUIZEN, Wim van den BRINK Regulatory Toxicology and Pharmacology, 2011, 59, 423-429. Doi : 10.1016/j.yrtph.2011.01.006 Abstract In 2007, the Minister of Health of the Netherlands requested the CAM (Coordination point Assessment and Monitoring new drugs) to assess the overall risk of magic mushrooms. The present paper is an updated redraft of the review, written to support the assessment by CAM experts. It summarizes the literature on physical or psychological dependence, acute and chronic toxicity, risk for public health and criminal aspects related to the consumption of magic mushrooms. In the Netherlands, the [...]
Lire la suiteMaternal Marijuana Use, Adverse Pregnacy Outcomes and Neonatal Morbidity, Torri D. Metz et al., 2017
Maternal Marijuana Use, Adverse Pregnancy Outcomes and Neonatal Morbidity Torri D. Metz, Ms Amanda A. Allshouse, Carol J. Rowland Hogue, Robert L. Goldenberg, Donald J. Dudley, Michael W. Varner, Deborah L. Conway, George R. Saade, and Robert M. Silver American Journal of Obstetrics and Gynecology, 2017 October ; 217, (4), 478.e1–478.e8. doi :10.1016/j.ajog.2017.05.050 Abstract Background—The NICHD Stillbirth Collaborative Research Network (SCRN) previously demonstrated an association between stillbirth and maternal marijuana use as defined by the presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC) in the umbilical cord homogenate. However, the relationship between marijuana use and perinatal complications in live births is uncertain. Objective—Our aim was to examine if [...]
Lire la suiteMedical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868 Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]
Lire la suiteLSD before Leary - Sidney Cohen' s Critique of 1950s Psychedelic Drug Research Steven J. Novak Isis, 1997, Vol. 88, No. 1, pp. 87-110. http://links.jstor.org/sici?sici=0021-1753%28199703%2988%3A1%3C87%3ALBLSCC%3E2.0.CO%3B2-W ABSTRACT In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD. LSD had arrived in the United States in 1949 and was originally perceived as a psychoto-mimetic capable of producing a model psychosis. But in the mid 1950s intellectuals in Southern California redefined LSD as a psychedelic capable of producing mystical enlightenment. Though LSD was an investigational drug, authorized only for experimental use, by the late 1950s psychiatrists and psychologists were [...]
Lire la suite